| Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164 DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Journal of Clinical Oncology 38 (1), 11, 2020 | 798 | 2020 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 375 | 2017 |
| ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ... Nature reviews Clinical oncology 17 (12), 757-770, 2020 | 265 | 2020 |
| Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study TS Bekaii-Saab, FS Ou, DH Ahn, PM Boland, KK Ciombor, EN Heying, ... The lancet oncology 20 (8), 1070-1082, 2019 | 241 | 2019 |
| Recent progress in Lynch syndrome and other familial colorectal cancer syndromes PM Boland, MB Yurgelun, CR Boland CA: a cancer journal for clinicians 68 (3), 217-231, 2018 | 170 | 2018 |
| Immunotherapy for colorectal cancer PM Boland, WW Ma Cancers 9 (5), 50, 2017 | 162 | 2017 |
| Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents N Yadav, S Kumar, T Marlowe, AK Chaudhary, R Kumar, J Wang, ... Cell death & disease 6 (11), e1969-e1969, 2015 | 125 | 2015 |
| Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study N Vijayvergia, PM Boland, E Handorf, KS Gustafson, Y Gong, HS Cooper, ... British journal of cancer 115 (5), 564-570, 2016 | 99 | 2016 |
| KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. DT Le, P Kavan, TW Kim, ME Burge, E Van Cutsem, H Hara, PMK Boland, ... Journal of Clinical Oncology 36 (15_suppl), 3514-3514, 2018 | 96 | 2018 |
| Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial JH Strickler, T Zemla, FS Ou, A Cercek, C Wu, FA Sanchez, J Hubbard, ... Annals of Oncology 30, v200, 2019 | 95 | 2019 |
| BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory … NB Mettu, E Twohy, FS Ou, TR Halfdanarson, HJ Lenz, R Breakstone, ... Annals of oncology 30, v203, 2019 | 70 | 2019 |
| Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy … P Gibbs, V Heinemann, NK Sharma, J Taieb, J Ricke, M Peeters, ... Clinical colorectal cancer 17 (4), e617-e629, 2018 | 68 | 2018 |
| Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)—An ACCRU … TS Bekaii-Saab, FS Ou, DM Anderson, DH Ahn, PMK Boland, ... J Clin Oncol 36 (4 Suppl), 611, 2018 | 64 | 2018 |
| The emerging role of neoadjuvant chemotherapy for rectal cancer PM Boland, M Fakih Journal of Gastrointestinal Oncology 5 (5), 362, 2014 | 56 | 2014 |
| Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial NB Mettu, FS Ou, TJ Zemla, TR Halfdanarson, HJ Lenz, RA Breakstone, ... JAMA Network Open 5 (2), e2149040-e2149040, 2022 | 54 | 2022 |
| Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label … JH Strickler, A Cercek, S Siena, T André, K Ng, E Van Cutsem, C Wu, ... The Lancet Oncology 24 (5), 496-508, 2023 | 53 | 2023 |
| Age-related rates of colorectal cancer and the factors associated with overall survival E Gabriel, K Attwood, E Al-Sukhni, D Erwin, P Boland, S Nurkin Journal of gastrointestinal oncology 9 (1), 96, 2018 | 51 | 2018 |
| Innate immunity to influenza virus: implications for future therapy MR White, M Doss, P Boland, T Tecle, KL Hartshorn Expert review of clinical immunology 4 (4), 497-514, 2008 | 50 | 2008 |
| Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas BG Smaglo, A Tesfaye, TR Halfdanarson, JE Meyer, J Wang, Z Gatalica, ... Oncotarget 6 (41), 43594, 2015 | 49 | 2015 |
| ZEBRA: a multicenter phase II study of pembrolizumab in patients with advanced small-bowel adenocarcinoma KS Pedersen, NR Foster, MJ Overman, PM Boland, SS Kim, ... Clinical Cancer Research 27 (13), 3641-3648, 2021 | 39 | 2021 |
